What is the role of oxidative stress in the development of diabetic peripheral neuropathy?

Year 2021, , 408 - 411, 01.05.2021

Tekin Yıldırım , Ramazan Önalan

https://doi.org/10.28982/josam.889008

Abstract

Background/aim: Diabetic peripheral neuropathy (DPN) is a clinical entity affecting approximately half of the patients with diabetes, impairing the quality of life. Patients usually do not receive full welfare despite medical treatment. This study aimed to evaluate the relationship between DPN and oxidative stress.
Methods: A single-center, clinical study was conducted on 80 patients with type 2 diabetes with and without peripheral neuropathy. Glucose, glycosylated hemoglobin (HbA1c), total oxidant capacity (status) (TOS), and total antioxidant capacity (status) (TAS) levels were assessed from blood samples collected from these individuals. Oxidative stress index (OSI) was calculated by the division of TOS to TAS.
Results: TAS levels were within the normal range while TOS and OSI levels were higher compared to individuals without diabetes in both groups. There was no significant difference between the groups in terms of TOS (P=0.26), TAS (P=0.85), and OSI (P=0.32) levels.
Conclusion: In our study, no relationship was found between DPN and oxidative stress. Further studies involving a larger number of diabetic patients with and without DPN are required to clarify the role of oxidative stress in the development of DPN.

Keywords

Diabetic peripheral neuropathy, Total oxidant status, Total antioxidant status, Oxidative stress, Oxidative stress index

References

• 1. Uzar E, Tamam Y, Evliyaoglu O, Tuzcu A, Beyaz C, Acar A et al. Serum prolidase activity and oxidative status in patients with diabetic neuropathy. Neurol Sci. 2012;33:875–80. doi 10.1007/s10072-011-0857-0.
• 2. Halifeoglu I, Karatas F, Colak R, Canatan H, Telo S. Oxidant and Antioxidant Status in Type 2 Diabetic Patients Before and After Therapy. Fırat Medical Journal. 2005;10:117-22.
• 3. Kesavulu MM, Rao BK, Giri R, Vijaya J, Subramanyam G, Approa CH. Lipid peroxidation and antioxidant enzyme status in Type 2 diabetics with coronary heart disease. Diabetes Research and Clinical Practice. 2001;53:33-9. doi: 10.1016/S0168-8227(01)00238-8.
• 4. Hunt JV, Smith CC, Wolff SP. Autoxidative glycosylation and the possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes. 1990;39:1420-24. doi: 10.2337/diab.39.11.1420.
• 5. Nathan MD, International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32:1327-34. doi: 10.2337/dc09-9033.
• 6. Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Brexulle J et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005;114:29-36. doi: 10.1016/j.pain.2004.12.010.
• 7. Unal-Cevik I, Sarioglu-Ay S, Evcik D. A comparison of the DN4 and LANSS questionnaires in the assessment of neuropathic pain: validity and reliability of the Turkish version of DN4. J Pain. 2010;11:1129-35. doi: 10.1016/j.jpain.2010.02.003.
• 8. Inci A, Olmaz R, Sarı F, Coban M, Ellidag HY, Sarıkaya M. Increased oxidative stress in diabetic nephropathy and its relationship with soluble Klotho levels. Hippokratia. 2016;20:198-203.
• 9. Aslan M, Sabuncu T, Kocyigit A, Celik H, Selek S. Relationship between total oxidant status and severity of diabetic nephropathy in type 2 diabetic patients. Nutr Metab Cardiovasc Dis. 2007;17:734–40.
• 10. Kasznicki J, Kosmalski M, Sliwinska A, Mrowicka M, Stanczyk M, Majsterek I et al. Evaluation of oxidative stress markers in pathogenesis of diabetic neuropathy. Mol Biol Rep. 2012;39:8669–78. doi: 10.1007/s11033-012-1722-9.
• 11. Sayın R, Aslan M, Kucukoglu ME, Luleci A, Atmaca M, Esen R et al. Serum prolidase enzyme activity and oxidative stress levels in patients with diabetic neuropathy. Endocrine. 2014;47:146–51. doi 10.1007/s12020-013-0136-3.
• 12. Ziegler D, Sohr C, Nourooz-Zadeh J. Oxidative Stress and Antioxidant Defense in Relation to the Severity of Diabetic Polyneuropathy and Cardiovascular Autonomic Neuropathy. Diabetes Care. 2004;27:2178–83. doi: 10.2337/diacare.27.9.2178.